On Monday, Organon & Co (NYSE: OGN) opened at On Monday, remained unchanged from the last session, before settling in for the closing price of $8.71. Price fluctuations for OGN have ranged from $8.05 to $23.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -6.67% over the past five years. Company’s average yearly earnings per share was noted -5.57% at the time writing. With a float of $259.02 million, this company’s outstanding shares have now reached $259.96 million.
Let’s look at the performance matrix of the company that is accounted for 10000 employees. In terms of profitability, gross margin is 57.18%, operating margin of 22.2%, and the pretax margin is 10.68%.
Organon & Co (OGN) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Organon & Co is 0.36%, while institutional ownership is 77.08%. The most recent insider transaction that took place on May 07 ’25, was worth 48,235. In this transaction Chief Human Resources Officer of this company bought 5,500 shares at a rate of $8.77, taking the stock ownership to the 62,974 shares. Before that another transaction happened on May 06 ’25, when Company’s Gen. Counsel & Corp. Secy. bought 8,045 for $9.21, making the entire transaction worth $74,054. This insider now owns 52,489 shares in total.
Organon & Co (OGN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.57% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.14% during the next five years compared to -23.49% drop over the previous five years of trading.
Organon & Co (NYSE: OGN) Trading Performance Indicators
Check out the current performance indicators for Organon & Co (OGN). In the past quarter, the stock posted a quick ratio of 1.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.36. Likewise, its price to free cash flow for the trailing twelve months is 2.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.89, a number that is poised to hit 0.92 in the next quarter and is forecasted to reach 4.00 in one year’s time.
Technical Analysis of Organon & Co (OGN)
Organon & Co (NYSE: OGN) saw its 5-day average volume 9.26 million, a positive change from its year-to-date volume of 4.49 million. As of the previous 9 days, the stock’s Stochastic %D was 14.84%. Additionally, its Average True Range was 0.81.
During the past 100 days, Organon & Co’s (OGN) raw stochastic average was set at 7.19%, which indicates a significant decrease from 12.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 143.67% in the past 14 days, which was higher than the 73.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.91, while its 200-day Moving Average is $16.34. Nevertheless, the first resistance level for the watch stands at $9.11 in the near term. At $9.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.79. If the price goes on to break the first support level at $8.43, it is likely to go to the next support level at $8.14. The third support level lies at $7.75 if the price breaches the second support level.
Organon & Co (NYSE: OGN) Key Stats
There are currently 259,956K shares outstanding in the company with a market cap of 2.26 billion. Presently, the company’s annual sales total 6,403 M according to its annual income of 864,000 K. Last quarter, the company’s sales amounted to 1,513 M and its income totaled 87,000 K.
